Aldosterone synthase inhibitors in cardiovascular and renal diseases. - Wikidata - awgldk - TriplyDB

Aldosterone synthase inhibitors in cardiovascular and renal diseases.

Aldosterone synthase inhibitors in cardiovascular and renal diseases.

http://www.wikidata.org/entity/Q38185015

about

Aldosterone Induces Renal Fibrosis and Inflammatory M1-Macrophage Subtype via Mineralocorticoid Receptor in Rats Update on RAAS Modulation for the Treatment of Diabetic Cardiovascular Disease Interfering with mineralocorticoid receptor activation: the past, present, and future The involvement of aldosterone on vascular insulin resistance: implications in obesity and type 2 diabetes.Discovery of Potential Inhibitors of Aldosterone Synthase from Chinese Herbs Using Pharmacophore Modeling, Molecular Docking, and Molecular Dynamics Simulation Studies.Endogenous cardiotonic steroids in kidney failure: a review and an hypothesis.ROMO1 links oxidative stress to mitochondrial integrity Third-generation Mineralocorticoid Receptor Antagonists: Why Do We Need a Fourth?An additive effect of eplerenone to ACE inhibitor on slowing the progression of diabetic nephropathy in the db/db mice.Spirolactone provides protection from renal fibrosis by inhibiting the endothelial-mesenchymal transition in isoprenaline-induced heart failure in rats.Cardiovascular actions of mineralocorticoid receptor antagonists in patients with chronic kidney disease: A systematic review and meta-analysis of randomized trials.The Evaluation and Therapeutic Management of Hypertension in the Transplant Patient.The potential of targeting CYP11B.Mega clinical trials which have shaped the RAS intervention clinical practice.Selectivity of BI 689648, a Novel, Highly Selective Aldosterone Synthase Inhibitor: Comparison with FAD286 and LCI699 in Nonhuman Primates.Metabolism of Oral Turinabol by Human Steroid Hormone-Synthesizing Cytochrome P450 Enzymes.Spironolactone ameliorates arterial medial calcification in uremic rats: the role of mineralocorticoid receptor signaling in vascular calcification.

P2860

Q27333455-C8EC2920-8668-470A-AA23-95E1697B94B8 Q28077454-FBD57654-4D67-4189-927B-38B39243A67A Q34019947-450663E0-0B19-4596-B0AA-4E0226B318BC Q34409899-62C4714E-BD2B-473D-BE7B-6824E2D3691A Q34543422-B962180B-FDAF-4924-9DB5-BA9ABD0FCAF5 Q35541172-F86E730D-B9D2-4895-9213-73CD0C528A17 Q35554485-AD7134DC-3BB3-4B19-9618-242F48F7B68A Q36437145-D73B97E7-11F0-4788-B818-54319DED6532 Q36878533-D29840EC-E044-441E-AC4F-ACEDA290D25C Q36887421-12C4895B-CA27-4403-A457-E3DE187084AB Q38382456-06DF0FB7-29F4-445D-8D33-996896F475E3 Q38585232-A6B2286F-BCA3-4037-855E-00A7F04C9F3C Q38725836-F96107E1-6EB0-47C2-A00A-4B2A248DDB9C Q38857792-BB6248F3-E236-4AF0-BE93-A2C344DCA345 Q51600686-6B07A248-A0C5-4443-86D5-B55926732549 Q52896121-CA0EEEDA-70D9-4E77-8ECE-9598B88A86AB Q53357907-1B08A78B-D3E1-43CB-809F-53A464506515

P2860

Aldosterone synthase inhibitors in cardiovascular and renal diseases.

http://www.wikidata.org/entity/Q38185015

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Aldosterone synthase inhibitors in cardiovascular and renal diseases.

@en

type

label

Aldosterone synthase inhibitors in cardiovascular and renal diseases.

@en

prefLabel

Aldosterone synthase inhibitors in cardiovascular and renal diseases.

@en

P1433

Q38185015-69C8483C-1F79-47A1-96A7-261C6FBF989B

P1476

Q38185015-048BC0C2-E0B8-4DEF-AE8B-6BA8F21156E5

P2093

Q38185015-A5D7043E-6E86-4C00-AB0C-07514635C663

P2860

Q38185015-0E155887-96CD-48AE-9328-D946A031FC78

Q38185015-140B4B65-A8F2-4B81-B327-98958171872B

Q38185015-187C895F-1B96-4C13-9D99-F441FF0C4423

Q38185015-1DB6756D-8387-41F8-A8D9-E00FE2633218

Q38185015-276EA322-4A86-466B-902D-F7EE2A34161E

Q38185015-2876BEF7-7418-4D52-AEE1-BB06B0A8FCF8

Q38185015-2B5C850A-4CC0-4ABF-AF9E-E8B44C3A98AF

Q38185015-2BEB4E07-AE31-465E-B3D1-385BCF0FAABE

Q38185015-358AB229-D461-4432-A577-B63EAE76DFD5

Q38185015-4A7845A0-915F-4964-9E99-20AA1902EA0E

P304

Q38185015-ED576103-C3ED-4A63-AB97-6DC46AF32C12

P31

Q38185015-C07B3826-21DA-4E66-AB8A-198250C74378

P356

Q38185015-F05D4678-6D81-4954-B6AD-245994C7E62D

P407

Q38185015-BD78112E-D68D-4360-90B9-BBB6C7AF4339

P478

Q38185015-8236AA6C-8946-44BA-B35B-749F679EC039

P50

Q38185015-461197C7-19C1-497C-BDF4-4CF542D39418

P577

Q38185015-A59E6773-2298-4263-93EE-E489C46B6BB6

P698

Q38185015-AF02FAAF-BBD7-4DFE-B32B-B9D9C4369B18

P356

P1433

Nephrology Dialysis Transplantation

P1476

Aldosterone synthase inhibitors in cardiovascular and renal diseases.

@en

P2093

Thomas Unger

http://www.w3.org/2001/XMLSchema#string

P2860

Aldosterone synthase inhibition in humans

3-Pyridyl substituted aliphatic cycles as CYP11B2 inhibitors: aromaticity abolishment of the core significantly increased selectivity over CYP1A2

Central infusion of aldosterone synthase inhibitor prevents sympathetic hyperactivity and hypertension by central Na+ in Wistar rats

Aldosterone mediates its rapid effects in vascular endothelial cells through GPER activation

Modulation of cytochromes P450 with xanthone-based molecules: from aromatase to aldosterone synthase and steroid 11β-hydroxylase inhibition.

Aldosterone biosynthesis, regulation, and classical mechanism of action.

Can the dextroenantiomer of the aromatase inhibitor fadrozole be useful for clinical investigation of aldosterone-synthase inhibition?

Aldosterone and cardiovascular disease: the heart of the matter.

Aldosterone-induced fibrosis in the kidney: questions and controversies

Aldosterone and the vascular system.

P304

i62-i68

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/NDT/GFT402

http://www.w3.org/2001/XMLSchema#string

P407

P478

29 Suppl 1

http://www.w3.org/2001/XMLSchema#string

P50

Pawel Namsolleck

P577

2014-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24493871

http://www.w3.org/2001/XMLSchema#string